التداخل بين دروبيريدول وغابابنتين

When the decision is made to co-prescribe NEURONTIN with another CNS depressant, particularly an opioid, or to prescribe NEURONTIN to patients with underlying respiratory impairment, monitor patients for symptoms of respiratory depression and sedation, and consider initiating NEURONTIN at a low dose.

Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when NEURONTIN is used with other drugs with sedative properties because of potential synergy.

Following the administration of droperidol, the dose of other CNS depressant drugs should be reduced.

As with other CNS depressant drugs, patients who have received droperidol should have appropriate surveillance.